Drug
Erenumab clinical trials
Also written Aimovig and AMG 334.
- studies test it
- 52
- open now
- 5
- in phase 3
- 10
- first study started
- 2012
Keep track of what changes. Save the erenumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
52 studies that test it; most in 2019 (15)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 15 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 16
- Phase 3
- 10
- Phase 4
- 16
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 32 · Other 20
Amgen (23) · Novartis Pharmaceuticals (7) · Danish Headache Center (6) · Mayo Clinic (4) · University of Maryland, Baltimore (2) · Indiana University (1) · Charite University, Berlin, Germany (1) · Merle Diamond (1)
Often tested with
Tested in the same studies.
Galcanezumab (3) · Eptinezumab (2) · Ubrogepant (1) · Atogepant (1) · Siltuximab (1) · Calcitonin Gene-Related Peptide (1) · Onabotulinum toxin A (1) · Fremanezumab (1)
Studies
Open first, then newest update. How each study uses erenumab is read from its arms, and is right about nine times in ten.
Testing it · 52
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH)RecruitingPhase 2Massachusetts General HospitalNCT05684692Written as Erenumab-Aooe
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Erenumab 70 mg
- Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBIRecruitingPhase 2Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05049057Written as Erenumab 140 Mg/mL Subcutaneous Solution
- Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With ErenumabRecruitingPhase 4Danish Headache CenterNCT04592952Written as Erenumab
- Registry for Migraine - Structural and Functional MRI Before and After Erenumab TreatmentRecruitingPhase 4Danish Headache CenterNCT04674020Written as Erenumab
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive, not recruitingPhase 3AmgenNCT03836040Written as Erenumab Dose 1
- Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineCompletedPhase 4AmgenNCT04252742Written as Erenumab
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineCompletedPhase 3AmgenNCT03832998Written as Erenumab Dose 1
- Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTHCompletedPhase 2Mayo ClinicNCT04098250Written as Erenumab
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03867201Written as Erenumab
- A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheCompletedPhase 4AmgenNCT03971071Written as Erenumab 70 mg
- Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular DisorderCompletedPhase 2Indiana UniversityNCT04884763Written as Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
- Investigational Use of Erenumab for the Treatment of Fibromyalgia PainWithdrawnPhase 3United States Naval Medical Center, PortsmouthNCT06411067Written as Erenumab
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label StudyCompletedPhase 4Novartis PharmaceuticalsNCT04084314Written as Erenumab
- A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineCompletedPhase 4AmgenNCT04825678Written as Erenumab
- Biomarker and Genetic Predictors of Erenumab Treatment ResponseCompletedPhase 4AmgenNCT04265755Written as Erenumab
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as Erenumab
- AMG 334 20160172 Pediatric Migraine PK Study.CompletedPhase 1AmgenNCT03499119Written as AMG 334 Dose 1
- Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)TerminatedPhase 2University of Maryland, BaltimoreNCT05162027Written as Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
- Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.TerminatedPhase 2University of Maryland, BaltimoreNCT05142228Written as Erenumab-Aooe
See all 52 studies that test erenumab →
As the comparator · 1 — what is tested is compared with erenumab
Codes
What other systems call erenumab · ClinicalTrials.gg INT000414
- MeSH (NLM) C000605816erenumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) I5I8VB78VTERENUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2045613Confirmed FDA, Wikidata
- Wikidata Q28209017erenumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169958ErenumabOne source FDA
- DrugBank DB14039One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605816 | erenumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | I5I8VB78VT | ERENUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2045613 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28209017 | erenumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169958 | Erenumab | One source FDA |
| DrugBank | DB14039 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.